Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AU 007

Next Previous
X
Search
Drug Profile

AU 007

Alternative Names: AU-007; BD-8; BDG8

Latest Information Update: 11 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biolojic Design
  • Developer Aulos Bioscience; Biolojic Design
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Interleukin-2 receptor alpha subunit antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 31 May 2024 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 24 May 2024 Updated pharmacokinetic, adverse events and efficacy data from a phase I/II trial in Solid tumours released by Aulos Bioscience
  • 16 May 2024 Aulos Bioscience enters into clinical trial and supply agreement with Ares Trading for use of Bavencio® (avelumab) in a clinical study of its lead human monoclonal antibody candidate, AU 007

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top